Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Agilysys Inc (AGYS) vs Baxter International Inc (BAX) Price & Performance

Agilysys Inc
Baxter International Inc

Price performance

Price movement over the last 24 hours

Key statistics

Agilysys Inc vs Baxter International Inc — how do they compare? Agilysys Inc trades at $107.67 (market cap $3.18B), while Baxter International Inc trades at $22.11 (market cap $11.81B). The key difference: Baxter International Inc is far larger — about 3.7× Agilysys Inc's market cap, and Baxter International Inc pays a 0.87% dividend while Agilysys Inc pays none. Which is the better fit depends on your goals.

AGYSBAX
Market Cap
$3.18B$11.81B
Sector
TechnologyHealth
52-Week High
$141.12$30.66
52-Week Low
$62.19$15.80
Enterprise Value
$3.08B$19.48B
Dividend Yield
0.87%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Agilysys Inc

Agilysys (AGYS) trades at $111.00, up 0.17% with strong bullish technical indicators and unanimous analyst support. The stock shows robust fundamentals with 62.61% gross margins and accelerating revenue growth, projected to reach $319 million in 2026. Recent earnings beats and positive guidance highlight the company's momentum in hospitality technology solutions.

The outlook remains positive with 100% buy ratings and a $110 consensus target, though high valuation multiples (P/E 81.05) and overbought RSI levels suggest near-term consolidation risks. Long-term growth drivers include AI integration and subscription revenue expansion, but investors should monitor execution against elevated expectations.

Baxter International Inc

Baxter International (BAX) trades at $22.86, up 0.93% today, near the consensus price target of $22.67. The stock shows a bullish technical trend with recent earnings beats in Q1 2026, though profitability remains weak with a negative net income margin of -9.7% and ROE of -16.73%. Cash flow trends indicate operational challenges, with net cash flow negative in recent periods. Recent news highlights sustainability initiatives and strategic partnerships, supporting a turnaround narrative amid ongoing financial restructuring.

Outlook: BAX presents a mixed opportunity with analyst consensus leaning Hold (52.77%) amid valuation concerns (P/E 87.85) and persistent losses. Key risks include high debt, margin pressure, and execution hurdles in stabilizing the business. Upside potential exists if operational improvements and AI integration drive sustained earnings recovery, but investors should weigh the high volatility and competitive pressures in the medtech sector.

Returns comparison

Trailing returns across standard periods

About Agilysys Inc

Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.

Read more on AGYS

About Baxter International Inc

Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.

Read more on BAX